Mawdsleys and Oncoscience launch a Named Patient Program for CIMAher® (Nimotuzumab) in the U.K. and Ireland
Oncoscience | October 3rd, 2018
Mawdsleys and Oncoscience GMbH have launched a Named Patient Supply Program to allow Oncologists in the United Kingd...
Oncoscience | May 21st, 2018
Oncoscience GmbH announced today that it has entered into an exclusive supply and distribution agreement with ...
Publication shows benefit in patients with locally advanced or metastatic pancreatic cancer treated with nimotuzumab in combination with gemcitabine.
Oncoscience | November 17th, 2017
New publication shows benefit in patients with locally advanced or metastatic pancreatic cancer treated with nimotuzumab...
Oncoscience | August 22nd, 2017
We are now Oncoscience GmbH. Managing directors are Dr. Dirk Reuter, Dr. Budhi Simon and Robert Ellerson....
Oncoscience AG attends the Nimotuzumab Global Scientific Meeting, 7th-10th April 2016 in Varadero/ Cuba
Oncoscience | April 7th, 2016
At this global clinical development meeting, more than 150 researches from over 20 countries discuss the latest results ...